Toward therapies for Friedreich ataxia

7 November 2023

Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) are pleased to invite you to a webinar on therapies for Friedreich ataxia.

This webinar is primarily targeted at Canadian clinicians, academics, and trainees with an interest in neuromuscular disease.

NMD4C and MDC are providing organizational and technical support. This is an independent clinical/academic webinar with no industry sponsorship or influence.

The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Chair and Speaker: Dr. Massimo Pandolfo

Dr. Massimo Pandolfo: Potential therapeutics for Friedreich ataxia: what is in the pipeline
Dr. David Lynch: TBD

Learning Objectives:
1. To become familiar with the genetics, pathology, clinical features of FA.
2. To learn about the natural history of FA, outcome measures and biomarkers for use in clinical trials.
3. To know the therapeutic approaches under study for FA.
4. To understand opportunities and challenges in the development of gene therapies for FA.

If you have any questions, please email

Further details

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit